CenExel Expands Clinical Research Footprint with $10M+ Site Upgrades
Event summary
- CenExel added 23,000+ sq. ft. of research space across five U.S. sites in early 2026, including specialized facilities for psychedelic dosing and neurodegenerative disease studies.
- $10M+ invested in Tampa (10K sq. ft.), Denver (5.3K sq. ft.), Anaheim (8K sq. ft.), Toms River, and Atlanta expansions to boost early-phase and CNS research capacity.
- Denver Phase I inpatient unit (11 rooms) set for June 2026 completion, targeting Alzheimer's/Huntington's/Parkinson's trials; Tampa expanding neurology capabilities by year-end.
- Atlanta's negative pressure exposure rooms secured two new nicotine-related studies within weeks of launch.
The big picture
CenExel's expansion reflects the growing demand for specialized clinical research infrastructure as biotech sponsors accelerate early-phase trials. The investments target high-growth therapeutic areas like CNS and metabolic disorders, where site capabilities often become development bottlenecks. With $10M+ deployed across five strategic locations, CenExel is positioning itself as a one-stop shop for complex studies, potentially attracting larger pharma partnerships.
What we're watching
- Therapeutic Focus
- How CenExel's neurodegenerative disease specialization will position it against competitors in high-growth CNS research.
- Operational Scale
- Whether the network can maintain quality control while rapidly expanding site capabilities nationwide.
- Sponsor Demand
- The pace at which new studies are awarded to these upgraded sites, particularly in psychedelics and metabolic research.